Alnylam Pharmaceuticals
ALNY
#564
Rank
NZ$73.83 B
Marketcap
NZ$556.70
Share price
0.51%
Change (1 day)
32.12%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024: -NZ$0.4 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$3.21 Billion. In 2024 the company made an earning of -NZ$0.4 Billion, an increase over its 2023 earnings that were of -NZ$0.53 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024-NZ$0.4 Billion-24.59%
2023-NZ$0.53 Billion-67.84%
2022-NZ$1.63 Billion36.93%
2021-NZ$1.19 Billion-8.04%
2020-NZ$1.29 Billion-15.66%
2019-NZ$1.53 Billion12.23%
2018-NZ$1.37 Billion62.91%
2017-NZ$0.84 Billion17.78%
2016-NZ$0.71 Billion43.44%
2015-NZ$0.5 Billion60.69%
2014-NZ$0.31 Billion98.2%
2013-NZ$0.16 Billion
2011-NZ$91.67 Million27.48%
2010-NZ$71.91 Million-10.92%
2009-NZ$80.72 Million95.77%
2008-NZ$41.24 Million
2006-NZ$66.06 Million-9.13%
2005-NZ$72.7 Million34.74%
2004-NZ$53.96 Million36.79%
2003-NZ$39.45 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
NZ$27.34 B 12,447.77%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$15.21 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$8.74 B 3,913.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-NZ$0.43 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-NZ$79.31 Million-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-NZ$0.27 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$3.59 B 1,551.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$0.23 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA